scholarly journals Combining Notch inhibition with current therapies for breast cancer treatment

2012 ◽  
Vol 5 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Keith Brennan ◽  
Robert B. Clarke
Keyword(s):  
Breast Cancer ◽  
Notch Pathway ◽  
Treatment Strategies ◽  
Breast Cancer Treatment ◽  
Notch Signalling ◽  
Cancer Therapies ◽  
Altered Expression ◽  
Current Therapies ◽  
Notch Inhibition ◽  
Tumour Initiation

Over recent years, there has been an increasing interest in targeting Notch signalling for the treatment of breast cancer. This has stemmed from the realization that many Notch pathway components display altered expression in breast cancer, and that Notch signalling impacts on many of the cellular properties associated with tumour initiation and progression. Consequently, Notch pathway inhibitors are now entering the initial stages of clinical trials. However, there is a definite need to consider how best to use these inhibitors and therefore which treatment strategies are likely to yield the most promising results. In particular, recent studies suggest that the greatest success will come from combining Notch pathway inhibitors with current breast cancer therapies.

scholarly journals Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3146
Author(s):  
Patricia Fernández-Nogueira ◽  
Gemma Fuster ◽  
Álvaro Gutierrez-Uzquiza ◽  
Pere Gascón ◽  
Neus Carbó ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptors ◽  
Treatment Strategies ◽  
Specific Treatment ◽  
Growth Factor Receptor ◽  
Cancer Associated Fibroblasts ◽  
Luminal A ◽  
Luminal B ◽  
Number Of Patients ◽  
Current Therapies

Breast cancer (BrCa) is the leading cause of death among women worldwide, with about one million new cases diagnosed each year. In spite of the improvements in diagnosis, early detection and treatment, there is still a high incidence of mortality and failure to respond to current therapies. With the use of several well-established biomarkers, such as hormone receptors and human epidermal growth factor receptor-2 (HER2), as well as genetic analysis, BrCa patients can be categorized into multiple subgroups: Luminal A, Luminal B, HER2-enriched, and Basal-like, with specific treatment strategies. Although chemotherapy and targeted therapies have greatly improved the survival of patients with BrCa, there is still a large number of patients who relapse or who fail to respond. The role of the tumor microenvironment in BrCa progression is becoming increasingly understood. Cancer-associated fibroblasts (CAFs) are the principal population of stromal cells in breast tumors. In this review, we discuss the current understanding of CAFs’ role in altering the tumor response to therapeutic agents as well as in fostering metastasis in BrCa. In addition, we also review the available CAFs-directed molecular therapies and their potential implications for BrCa management.

Conservation of the Notch signalling pathway in mammalian neurogenesis

Development ◽  
1997 ◽  
Vol 124 (6) ◽  
pp. 1139-1148 ◽  
Author(s):  
J.L. Pompa de la ◽  
A. Wakeham ◽  
K.M. Correia ◽  
E. Samper ◽  
S. Brown ◽  
...  
Keyword(s):  
Cell Fate ◽  
Notch Pathway ◽  
Stem Cell Differentiation ◽  
Notch Signalling ◽  
Signalling Pathway ◽  
Notch Signalling Pathway ◽  
Altered Expression ◽  
Cell Fate Decisions ◽  
Targeted Mutation ◽  
Multiple Cell

The Notch pathway functions in multiple cell fate determination processes in invertebrate embryos, including the decision between the neuroblast and epidermoblast lineages in Drosophila. In the mouse, targeted mutation of the Notch pathway genes Notch1 and RBP-Jk has demonstrated a role for these genes in somite segmentation, but a function in neurogenesis and in cell fate decisions has not been shown. Here we show that these mutations lead to altered expression of the Notch signalling pathway homologues Hes-5, Mash-1 and Dll1, resulting in enhanced neurogenesis. Precocious neuronal differentiation is indicated by the expanded expression domains of Math4A, neuroD and NSCL-1. The RBP-Jk mutation has stronger effects on expression of these genes than does the Notch1 mutation, consistent with functional redundancy of Notch genes in neurogenesis. Our results demonstrate conservation of the Notch pathway and its regulatory mechanisms from fly to mouse, and support a role for the murine Notch signalling pathway in the regulation of neural stem cell differentiation.

scholarly journals Targeting Breast Cancer Metastasis

2015 ◽  
Vol 9s1 ◽  
pp. BCBCR.S25460 ◽  
Author(s):  
Xin Jin ◽  
Ping Mu
Keyword(s):  
Breast Cancer ◽  
Cancer Metastasis ◽  
Treatment Strategies ◽  
Breast Cancer Metastasis ◽  
Therapeutic Targeting ◽  
Distant Relapse ◽  
Current Therapies

Metastasis is the leading cause of breast cancer-associated deaths. Despite the significant improvement in current therapies in extending patient life, 30–40% of patients may eventually suffer from distant relapse and succumb to the disease. Consequently, a deeper understanding of the metastasis biology is key to developing better treatment strategies and achieving long-lasting therapeutic efficacies against breast cancer. This review covers recent breakthroughs in the discovery of various metastatic traits that contribute to the metastasis cascade of breast cancer, which may provide novel avenues for therapeutic targeting.

Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment

2018 ◽  
Vol 18 (7) ◽  
pp. 629-639 ◽  
Author(s):  
Natalia Lisiak ◽  
Ewa Toton ◽  
Maria Rybczynska
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Hormone Receptors ◽  
Molecular Subtypes ◽  
Treatment Strategies ◽  
Breast Cancer Treatment ◽  
Therapy Failure ◽  
Potential Therapeutic Target ◽  
Apoptotic Pathway ◽  
Transduction Mechanisms

One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor or hormone receptors. Many types of breast cancer exhibit different abnormalities in the apoptotic pathway, which confer the resistance to many forms of chemotherapy. Because of the fundamental importance of autophagy in the development and progression of cancer and its ability to affect treatment response, there has been an immense research on molecular regulation and signal transduction mechanisms that control this process. Here, we summarize the present knowledge concerning different breast cancer treatment strategies using drugs approved for the treatment of different breast cancer molecular subtypes with targeting pathways and factors associated with autophagy modulation/ regulation.

Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options

2021 ◽  
Vol 21 ◽  
Author(s):  
Kavita Singh ◽  
Dhananjay Yadav ◽  
Meenu Jain ◽  
Pramod Kumar Singh ◽  
Jun-O Jin
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Immune Checkpoint ◽  
Checkpoint Inhibitors ◽  
Treatment Strategies ◽  
Growth Factor Receptor ◽  
Breast Cancer Treatment ◽  
Current Evidence ◽  
New Paradigm ◽  
Her2 Positive

: Breast cancer (BC) stands at the first position among all forms of malignancies found in women globally. The available therapeutic approaches for breast cancer includes chemotherapy, radiation therapy, hormonal therapy and finally surgery. Despite the conventional therapies, in recent years the advance immunology based therapeutics emerge a potential in breast cancer treatment, including immune checkpoint blockades, vaccines and in combination with other treatment strategies. Although, commonly used treatments like trastuzumab/pertuzumab for human epidermal growth factor receptor 2 (Her2) positive and hormone therapy for estrogen receptor (ER) positive and/or progesterone receptor (PR) positive BC are specific but triple negative breast cancer (TNBC) cases remain a great challenge for treatment measures. Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.

scholarly journals Role of magnetic resonance imaging in the planning of breast cancer treatment strategies: comparison with conventional imaging techniques

2017 ◽  
Vol 50 (2) ◽  
pp. 76-81 ◽  
Author(s):  
Luciana Karla Lira França ◽  
Almir Galvão Vieira Bitencourt ◽  
Hugo Lamartine Souza Paiva ◽  
Caroline Baptista Silva ◽  
Nara Pacheco Pereira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Treatment Strategies ◽  
Breast Mri ◽  
Breast Cancer Treatment ◽  
Pathological Examination ◽  
Conventional Imaging ◽  
Resonance Imaging

Abstract Objective: To assess the role of magnetic resonance imaging (MRI) in the planning of breast cancer treatment strategies. Materials and Methods: The study included 160 women diagnosed with breast cancer, who underwent breast MRI for preoperative staging. Using Pearson's correlation coefficient (r), we compared the size of the primary tumor, as determined by MRI, by conventional imaging (mammography and ultrasound), and in the pathological examination (gold standard). The identification of lesions not identified in previous examinations was also evaluated, as was its influence on treatment planning. Results: The mean age of the patients was 52.2 years (range, 30-81 years), and the most common histological type was invasive ductal carcinoma (in 60.6% of the patients). In terms of the tumor size determined, MRI correlated better with the pathological examination than did mammography (r = 0.872 vs. 0.710) or ultrasound (r = 0.836 vs. 0.704). MRI identified additional lesions in 53 patients (33.1%), including malignant lesions in 20 (12.5%), which led to change in the therapeutic planning in 23 patients (14.4%). Conclusion: Breast MRI proved to be more accurate than conventional imaging in determining the dimensions of the main tumor and was able to identify lesions not identified by other methods evaluated, which altered the therapeutic planning in a significant proportion of cases.

scholarly journals Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review

2021 ◽  
Vol 12 ◽  
Author(s):  
Yanqi Ye ◽  
Chun Xu ◽  
Fengqian Chen ◽  
Qi Liu ◽  
Ning Cheng
Keyword(s):  
Breast Cancer ◽  
Innate Immunity ◽  
Patient Outcomes ◽  
Tumor Metastasis ◽  
Treatment Strategies ◽  
Innate Immune ◽  
Cancer Therapies ◽  
Immune Microenvironment ◽  
Tumor Immune Microenvironment ◽  
Control Tumor

Although breast cancer has been previously considered “cold” tumors, numerous studies are currently conducted to explore the great potentials of immunotherapies in improving breast cancer patient outcomes. In addition to the focus on stimulating adaptive immunity for antitumor responses, growing evidence showed the importance of triggering host innate immunity to eradicate established tumors and/or control tumor metastasis of breast cancer. In this review, we first briefly introduce the breast tumor immune microenvironment. We also discuss innate immune targets and pathways and mechanisms of their synergy with the adaptive antitumor response and other treatment strategies. Lastly, we review clinical trials targeting innate immune pathways for breast cancer therapies.

Sign in / Sign up

Export Citation Format

Share Document